Get the Stockscreener App
177.47
1.60%
-2.88
After Hours:
177.47
Glaukos Corp stock is traded at $177.47, with a volume of 572.52K.
It is down -1.60% in the last 24 hours and up +4.07% over the past month.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
See More
Previous Close:
$180.35
Open:
$177.8
24h Volume:
572.52K
Relative Volume:
0.68
Market Cap:
$10.47B
Revenue:
$551.35M
Net Income/Loss:
$-189.33M
P/E Ratio:
-53.92
EPS:
-3.2916
Net Cash Flow:
$-35.09M
1W Performance:
-1.33%
1M Performance:
+4.07%
6M Performance:
+53.83%
1Y Performance:
+96.88%
1-Day Range:
$175.13
$181.52
1-Week Range:
$174.28
$182.28
52-Week Range:
$73.16
$191.62
Glaukos Corp Stock (GKOS) Company Profile
Name
Glaukos Corp
Sector
Industry
Phone
949-367-9600
Address
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corp
|
177.47 | 10.91B | 551.35M | -189.33M | -35.09M | -3.2916 |
ABT
Abbott Laboratories
|
108.33 | 197.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.17 | 118.14B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
303.13 | 125.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
47.80 | 71.55B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.90 | 51.78B | 6.30B | 1.07B | 1.09B | 1.8406 |
Glaukos Corp Stock (GKOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-06-26 | Initiated | H.C. Wainwright | Buy |
| Oct-27-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-01-25 | Initiated | Goldman | Buy |
| May-01-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-19-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-11-24 | Upgrade | Citigroup | Neutral → Buy |
| Dec-06-24 | Initiated | UBS | Buy |
| Dec-02-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-10-24 | Downgrade | Citigroup | Buy → Neutral |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-21-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-28-23 | Initiated | Truist | Buy |
| Nov-08-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-07-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-19-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Oct-04-22 | Initiated | Needham | Buy |
| Jul-12-22 | Upgrade | Stifel | Hold → Buy |
| Feb-03-22 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-19-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jan-18-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Jul-26-21 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jul-20-21 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jul-14-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-08-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Upgrade | Citigroup | Sell → Neutral |
| Dec-09-20 | Initiated | Oppenheimer | Perform |
| Nov-17-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-08-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-15-20 | Initiated | Jefferies | Hold |
| Mar-05-20 | Initiated | Citigroup | Sell |
| Feb-28-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-20 | Upgrade | Berenberg | Hold → Buy |
| Dec-12-19 | Downgrade | Wells Fargo | Outperform → Underperform |
| Sep-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Mar-08-19 | Initiated | BTIG Research | Neutral |
| Aug-30-18 | Initiated | Berenberg | Hold |
| Aug-29-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-03-18 | Reiterated | Stifel | Hold |
| Jun-21-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-13-18 | Downgrade | Stifel | Buy → Hold |
| Mar-01-18 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-02-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-06-17 | Upgrade | Stifel | Hold → Buy |
| Oct-27-16 | Initiated | Wells Fargo | Outperform |
View All
Glaukos Corp Stock (GKOS) Latest News
Enterprise value to EBITDA forward of Glaukos Corp – LSX:A14VCK - TradingView
Precipio Inc. (PRPO) Peer Comparison – Compare with Others - Value Research
Mesa Laboratories Inc. (MLAB) Peer Comparison – Compare with Others - Value Research
Bruker Corporation (BRKR) Peer Comparison – Compare with Others - Value Research
Heska Corporation (HSKA) Peer Comparison – Compare with Others - Value Research
Natus Medical Incorporated (NTUS) Peer Comparison – Compare with Others - Value Research
Repro Med Systems Inc. (KRMD) Peer Comparison – Compare with Others - Value Research
Allied Healthcare Products Inc. (AHPI) Peer Comparison – Compare with Others - Value Research
Codex DNA Inc (DNAY) Peer Comparison – Compare with Others - Value Research
GlucoTrack Inc (GCTK) Peer Comparison – Compare with Others - Value Research
InspireMD Inc. (NSPR) Peer Comparison – Compare with Others - Value Research
IsoPlexis Corporation (ISO) Peer Comparison – Compare with Others - Value Research
Glaukos chief development officer sells $2.48m in shares - Investing.com
Glaukos chief development officer sells $2.48m in shares By Investing.com - Investing.com Canada
Haemonetics Corporation (HAE) Peer Comparison – Compare with Others - Value Research
Glaukos stock trades at $179 as investors weigh recent growth and valuation - AD HOC NEWS
ICU Medical Inc. (ICUI) Peer Comparison – Compare with Others - Value Research
Trinity Biotech plcADR Peer Comparison – Compare with Others - Value Research
Acutus Medical Inc (AFIB) Peer Comparison – Compare with Others - Value Research
SS Innovations International Inc. (SSII) Peer Comparison – Compare with Others - Value Research
Bioventus Inc. Class A (BVS) Peer Comparison – Compare with Others - Value Research
Omnicell Inc. ($0.001 par value) (OMCL) Peer Comparison – Compare with Others - Value Research
MaxCyte Inc. (MXCT) Peer Comparison – Compare with Others - valueresearchonline.com
Repligen Corporation (RGEN) Peer Comparison – Compare with Others - Value Research
Glaukos Corp (GKOS) Key Financial Ratios – Valuation, Profitability & More - Value Research
Glaukos (NYSE: GKOS) insider eyes multimillion-dollar stock sale - Stock Titan
Aethlon Medical Inc. (AEMD) Peer Comparison – Compare with Others - Value Research
Vivos Therapeutics Inc. (VVOS) Peer Comparison – Compare with Others - Value Research
Dentsply Sirona Inc (XRAY) Peer Comparison – Compare with Others - Value Research
Myriad Genetics Inc. (MYGN) Peer Comparison – Compare with Others - Value Research
TransMedics Group Inc. (TMDX) Peer Comparison – Compare with Others - Value Research
Innovative Eyewear Inc (LUCYW) Peer Comparison – Compare with Others - Value Research
Glaukos Corp (GKOS) Peer Comparison – Compare with Others - Value Research
Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today - Benzinga
Why Is Glaukos (NYSE:GKOS) in Focus After Record Quarterly Sales? - Kalkine Media
Zacks Research Issues Positive Estimate for Glaukos Earnings - MarketBeat
Glaukos (GKOS) Stock Looks Pricey On High Growth Expectations - Sahm
BlackRock Inc. Takes Position in Glaukos Corporation $GKOS - MarketBeat
Glaukos Corp stock hits all-time high at 190.27 USD By Investing.com - Investing.com South Africa
Glaukos director Kliman sells $475,000 in shares - Investing.com
Glaukos (NYSE:GKOS) Director Gilbert Kliman Sells 2,500 Shares of Stock - MarketBeat
Glaukos (NYSE: GKOS) director sells shares after option exercise - Stock Titan
GKOS Stock Surges 67% Year to Date: What's Driving the Rally? - Yahoo Finance
Glaukos Corp stock hits all-time high at 190.27 USD - Investing.com
BTIG Research Boosts Glaukos (NYSE:GKOS) Price Target to $202.00 - MarketBeat
Zacks Research Has Negative Outlook for Glaukos Q2 Earnings - MarketBeat
GKOS Maintained by BTIG -- Price Target Raised to $202 - GuruFocus
Glaukos (NYSE:GKOS) Reaches New 12-Month HighShould You Buy? - MarketBeat
Glaukos (NYSE: GKOS) holder to sell 2,500 shares in 2026 - Stock Titan
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now - Yahoo Finance
Glaukos Announces Participation in Wells Fargo Healthcare Conference - Business Wire
Glaukos Corp Stock (GKOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Glaukos Corp Stock (GKOS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kliman Gilbert H | Director |
Aug 19 '26 |
Option Exercise |
25.77 |
2,500 |
64,425 |
39,906 |
| Kliman Gilbert H | Director |
Aug 19 '26 |
Sale |
190.00 |
2,500 |
475,000 |
37,406 |
0.86%
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):